Sonlicromanol

Khondrion BV is running KHENERFIN, a Phase 3 trial of sonlicromanol in adults with primary mitochondrial disease and persistent fatigue. The primary endpoint is patient-reported fatigue on the Neuro-QoL scale, a subjective measure that has tripped up other drugs in this space [2]. The most direct precedent is elamipretide's MMPOWER-3 trial - 218 patients with primary mitochondrial myopathy, a PMMSA fatigue co-primary endpoint, which failed in 2022 and was published in Neurology in 2023 [8]. KHENERFIN's design - 220 patients, fatigue primary, genetically confirmed mitochondrial disease - is nearly the same shape of bet. If sonlicromanol hits, it becomes one of the first approved disease-modifying agents for primary mitochondrial disease, a category where the only widely-used option (idebenone) is approved in Europe for Leber's hereditary optic neuropathy but not in the US for most mitochondrial indications. Khondrion is a private Dutch biotech spun out of Radboud University and has built its entire pipeline around this one molecule, originally coded KH176. The Phase 3 follows a Phase 2b program in m.3243A>G mutation carriers published in Brain in 2025, which reported statistically significant improvements on cognition (Test of Attentional Performance Alertness subscale), pain, depression, physical component scores, and balance/mobility - but no single, clean primary endpoint hit across the integrated program [1]. This is a single-shot registration program for a small sponsor in a graveyard indication. The asymmetry is real, but so is the downside.

Sonlicromanol (KH176) is a novel compound, never approved anywhere, moving through Phase 3 in primary mitochondrial disease. KHENERFIN (NCT06451757) opened recruitment in 2024 and is enrolling 220 patients [2]. The compound holds EMA orphan drug designation for mitochondrial disease, granted years ago when earlier-phase work began, which carries 10-year market exclusivity in the EU if approved. No FDA breakthrough or fast-track designation has been publicly disclosed, which matters: FDA has not signaled that this program clears their bar for regulatory acceleration. Earlier work includes the completed KHENERGYZE Phase 2 in cognition (NCT04165239) [4] and the KHENERGYC pediatric Phase 2 in children with genetically confirmed mitochondrial disease (PMID 35477351) [3]. The integrated Phase 2b program in m.3243A>G adults (KHENERGY crossover + KHENERGYZE parallel) was published in Brain in 2025 [1]. Primary endpoint in KHENERFIN is measured at 24 weeks. Realistic topline sits in 2027 if enrollment completes on schedule, with a regulatory submission potentially in 2028. A separate Phase 2 in Post-COVID fatigue with post-exertional malaise (SON4PEM, NCT07298005, n=80, 13-week treatment, FAS primary endpoint) dosed its first patient in May 2026 under investigator sponsorship from Amsterdam UMC with ZonMw funding rather than Khondrion's registration program [5]. That tells you ROS modulation is being explored beyond rare mitochondrial disease, but Khondrion itself remains focused on the rare disease registration path.

Mitochondria are the cellular structures that turn food and oxygen into usable energy (ATP). In primary mitochondrial diseases, mutations in mitochondrial DNA, most commonly m.3243A>G, break this energy machinery. The damaged mitochondria leak excess reactive oxygen species (ROS), highly reactive molecules that act like sparks in a fuel tank, damaging proteins, lipids, and DNA. The result: progressive failure of energy-hungry tissues like brain, muscle, heart, and kidney. Sonlicromanol is a small molecule built around a chromanol core, the same chemical scaffold as vitamin E. It does two things. First, it scavenges ROS directly inside the mitochondrion. Second, it modulates a redox-sensitive enzyme called soluble PGES-1, which dampens downstream inflammation triggered by oxidative stress. How strong is the mechanism case? Honestly, medium. ROS biology in mitochondrial disease is well-documented at the cell level, and animal models show benefit. But the broader thesis that scavenging ROS or buffering oxidative stress translates to clinical benefit has been tested repeatedly by idebenone, MitoQ, vatiquinone (formerly EPI-743, an alpha-tocotrienol quinone from Edison Pharma now owned by PTC Therapeutics), and elamipretide (Stealth BioTherapeutics, a tetrapeptide that stabilizes cardiolipin), with results ranging from weak to negative on registration endpoints. Sonlicromanol's PGES-1 angle is its differentiator versus pure antioxidants, but that piece of the mechanism is the least clinically validated.

KHENERFIN (NCT06451757) is a Phase 3 randomized, placebo-controlled, double-blind trial enrolling 220 adults with genetically confirmed primary mitochondrial disease and clinically significant fatigue [2]. Patients receive sonlicromanol or placebo for 24 weeks. The primary endpoint is change in the Neuro-QoL Fatigue Short Form v1, a patient-reported outcome. Three design concerns deserve flagging. First, the endpoint is entirely subjective. Patient-reported fatigue in rare diseases is notoriously sensitive to placebo response, and a recent analysis of goal attainment scales in primary mitochondrial disease trials documented exactly this measurement-noise problem (PMID 41806562) [6]. Second, the patient population spans a wide genotypic and clinical range. Primary mitochondrial disease is not one disease - it includes MELAS, MIDD, KSS, CPEO, and others. If KHENERFIN pools large-deletion patients (KSS, CPEO) with point-mutation patients (MELAS, MIDD driven by m.3243A>G), the biology is genuinely different and the trial gets noisier still. Pooling across mutations gives statistical power but obscures whether any particular subgroup is the real responder. A pre-specified subgroup analysis in m.3243A>G carriers (the largest mutation group and the focus of the Phase 2b [1]) would be the cleanest path to interpretable data; the enrollment split by genotype has not been publicly disclosed. Third, the structural parallel to elamipretide MMPOWER-3 is hard to ignore: 218 vs 220 patients, fatigue-related PRO co-primary, genetically confirmed mitochondrial disease, failed in 2022 [8]. Comparator is placebo, which is appropriate given no approved standard of care for this fatigue indication. Enrollment status as of mid-2026 is recruiting per the NCT record, with no public timeline for last-patient-in. A realistic primary completion sits in 2027.

Our model gives this drug an 11% chance of eventually being approved. That figure starts from the historical approval rate for Phase 3 drugs in this area - about 51% - then adjusts based on ten specific facts about the trial and its sponsor. The estimate is pulled down mainly by heavier-than-usual blinding, the sponsor's thin or weak approval record, limited earlier-phase results, and the trial's randomized design. The remaining factors are close to average for this stage, so they don't move the number much in either direction.

Efficacy risk dominates. The fatigue endpoint is subjective and placebo-prone in rare disease populations. Mitochondrial disease patients enroll motivated and hopeful, which inflates placebo response. A 4-6 point swing in Neuro-QoL fatigue scores is clinically meaningful but easily masked by noise in 220 patients split across multiple mutations [2]. The most directly applicable failed precedent is elamipretide MMPOWER-3: 218 patients with genetically confirmed primary mitochondrial myopathy, daily subcutaneous dosing for 24 weeks, fatigue (PMMSA Total Fatigue Score) as a co-primary with 6MWT, missed both endpoints despite signals in earlier-phase work [8]. KHENERFIN is a structurally similar bet with a sister-class mechanism. The other relevant misses are vatiquinone (formerly EPI-743, Edison Pharma compound acquired by PTC) in two 2023 Phase 3 reads - MIT-E in mitochondrial disease-associated seizures [7] and MOVE-FA in Friedreich's ataxia [9]. The Phase 2b data, while published in Brain, did not deliver a single dominant primary endpoint hit - the case is built on consistent secondary improvements across cognition, pain, depression, physical function, and balance, which is suggestive rather than definitive [1]. Safety risk is moderate. ROS scavengers are generally well-tolerated, and chromanol chemistry has decades of human exposure via vitamin E. No specific safety signal has been disclosed across Khondrion's Phase 2 program [3][4]. The sPGES-1 modulation could in theory affect prostaglandin biology, relevant for cardiovascular and renal physiology, but no clinical signal has surfaced. Execution risk is real. Khondrion is a small private biotech with one molecule and an opaque funding runway - no recent disclosed financing round has been made public, and the company depends on grant/partnership inflows. Enrollment of 220 rare-disease patients is slow even with engaged patient organizations. Any single-trial registration program is fragile because there is no backup study running in parallel. Commercial risk: even if approved, the primary mitochondrial disease population in developed markets is roughly 20,000-40,000 diagnosed adults. Pricing will have to clear $200K+ per year to make the math work, and payers will demand strong endpoint data given the subjective primary. A modest fatigue improvement approval will struggle with reimbursement. Idebenone's commercial trajectory in Leber's hereditary optic neuropathy is the realistic ceiling.

Worth watching, with caveats. The signal to monitor is the m.3243A>G subgroup result whenever Khondrion releases topline data. That is the only clean read on whether ROS modulation actually moves the needle in the disease where the mechanism has the strongest cell-biology rationale and where the Phase 2b ran [1]. If the overall trial hits and the m.3243A>G subgroup is consistent, this is a real drug. If the overall hits but the subgroup is flat, it is a placebo response story and the drug will struggle at FDA. If both miss, sonlicromanol joins elamipretide, idebenone, and vatiquinone in the primary mitochondrial disease graveyard [7][8][9]. Check back in late 2027 for the primary completion timeline update on ClinicalTrials.gov [2]. Earlier signals to watch: any acquisition of Khondrion or a partnership announcement, which would change the program's resource profile and address the funding-opacity problem, and any FDA breakthrough designation, which has not been granted to date despite the EMA orphan status. Both would be material upgrades. Khondrion itself is the constraint. They are private, focused entirely on this molecule, and their cash runway is not publicly disclosed. A larger pharma partner taking commercial rights would de-risk execution substantially. Without that, even a positive trial will face a hard path to US launch given the limited commercial infrastructure of a single-asset Dutch biotech.